137Table 4.9 (continued)Drug Therapeutic area Gene Referenced subgroup
Fluorouracil (1) Dermatology DPYD DPD defi cient
Fluorouracil (2) Oncology DPYD DPD defi cient
Fluoxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Flurbiprofen Rheumatology CYP2C9 CYP2C9 poor metabolizers
Fluvoxamine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Fulvestrant Oncology ESR1 Estrogen receptor positive
Galantamine Neurology CYP2D6 CYP2D6 poor metabolizers
Gefi tinib Oncology EGFR EGFR protein expression
positive
Glimepiride Endocrinology G6PD G6PD defi cient
Glipizide Endocrinology G6PD G6PD defi cient
Glyburide Endocrinology G6PD G6PD defi cient
Ibritumomab tiuxetan Oncology MS4A1 CD20 positive
Iloperidone Psychiatry CYP2D6 CYP2D6 poor metabolizers
Imatinib (1) Oncology KIT c-KIT D816V mutation
negative
Imatinib (2) Oncology BCR/ABL1 Philadelphia chromosome
(t(9;22)) positive
Imatinib (3) Oncology PDGFRB PDGFR gene
rearrangement positive
Imatinib (4) Oncology FIP1L1/PDGFRA FIP1L1/PDGFRα fusion
kinase (or CHIC2
deletion) positive
Imipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Indacaterol Pulmonary UGT1A1 UGT1A1 28 allele
homozygotes
Irinotecan Oncology UGT1A1 UGT1A128 allele carriers
Isosorbide and
hydralazine
Cardiology NAT1-2 Slow acetylatorsIvacaftor Pulmonary CFTR CFTR G551D carriers
Lansoprazole Gastroenterology CYP2C19 CYP2C19 poor metabolizer
Lapatinib Oncology ERBB2 HER2 protein
Lenalidomide Hematology del (5q) Chromosome 5q deletion
Letrozole Oncology ESR1, PGR Hormone receptor positive
Lomitapide Endocrinology LDLR Homozygous familial
hypercholesterolemia
and LDL receptor
mutation defi cient
Mafenide Infectious diseases G6PD G6PD defi cient
Maraviroc Infectious diseases CCR5 CCR5 positive
Mercaptopurine Oncology TPMT TPMT intermediate or poor
metabolizers
Methylene Blue Hematology G6PD G6PD defi cient
Metoclopramide Gastroentrology CYB5R1-4 NADH cytochrome b5
reductase defi cient
Metoprolol Cardiology CYP2D6 CYP2D6 poor metabolizers
(continued)